Medicines Co /de (MDCO): Robert G. Savage , director of Medicines Co /de sold 10,000 shares on May 24, 2016. The Insider selling transaction was reported by the company on May 26, 2016 to the Securities and Exchange Commission. The shares were sold at $36.95 per share for a total value of $369,500.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 26, 2016, Melvin K Spigelman (director) sold 15,000 shares at $37.00 per share price.On May 18, 2016, William Crouse (director) sold 15,000 shares at $35.15 per share price.Also, On May 18, 2016, Clive Meanwell (CEO) sold 10,000 shares at $35.00 per share price.On May 13, 2016, Fredric N Eshelman (director) purchased 300,000 shares at $33.68 per share price.
Shares of The Medicines Company (MDCO) ended Wednesday, May 25, 2016 session in red amid volatile trading. The shares closed down -0.12 points or -0.32% at $37.17 with 4,88,467 shares getting traded. Post opening the session at $37.42, the shares hit an intraday low of $37.01 and an intraday high of $37.9 and the price vacillated in this range throughout the day. The company has a market cap of $2,605 M and the number of outstanding shares has been calculated to be 7,00,72,431 shares. The 52-week high of The Medicines Company is $43.79 and the 52-week low is $25.38.
Company has been under the radar of several Street Analysts.The Medicines Company is Reiterated by Chardan Capital Markets to Buy and the brokerage firm has raised the Price Target to $ 65 from a previous price target of $50 .The Rating was issued on Mar 21, 2016.
The Medicines Company is a global biopharmaceutical company. The Company’s marketed products are: Angiomax (bivalirudin) Cleviprex (clevidipine) injectable emulsion Minocin (minocycline) for injection Orbactiv (oritavancin) PreveLeak and Recothrom Thrombin topical (Recombinant). The Company’s products in development include its registration stage product candidates and its research and development product candidates. It has a pipeline of acute and intensive care hospital products in development including four registration stage product candidates for which the Company has submitted applications for regulatory approval in the United States cangrelor IONSYS (fentanyl iontophoretic transdermal system) Raplixa formerly referred to as Fibrocaps and RPX-602. The Company’s four research and development product candidates include ABP-700 ALN-PCSsc Carbavance and MDCO-216. The Company also develops ABP-700 an intravenous anesthetic which is in Phase I of clinical studies.